ウェビナー動画：次世代シーケンス（NGS）による細胞治療製品の製造における品質管理（QC）について

In this webinar, Anukana Bhattacharjee, Scientific Consultant from Genedata Selector, demonstrates how Genedata Selector^® supports cell therapy production and critical quality attribute assessments (CQAs) by using NGS as a Multi-Attribute-Method (MAM). Using data obtained from the Fraunhofer Institute for Interfacial Engineering Biosafety and Biotechnology IGB in Stuttgart, Germany, Anukana illustrates how Genedata Selector supports NGS-based adventitious agent detection, correct variant introduction, and differential gene expression assessment. The outcome of the analyzed dataset is a single, unified overview of QC results across all run NGS-based analyses. Using customized and standardized Playbooks, Anukana demonstrates how to turn complex NGS assays into automated and simplified streamlined workflows. Additionally, she shows how Genedata Selector provides actionable go/no-go signals for better-informed decision-making regarding critical quality testing of cell therapy products. 

This talk was given as part of our regular Open Forums on NGS-based QC for advancing drug development and manufacturing. 

Who should watch? 

Biopharma and biotech professionals looking to advance analytical development, biosafety, and QC testing for CGT products by embracing digitalization and innovative enterprise data analysis systems.